# BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
> **ANDA218766** · Abbreviated New Drug Application (Generic) · Sponsor: CIPLA LTD · Approved 2025-10-14
## Drug
- **FDA Application Number:** ANDA218766
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
- **Generic name:** Bictegravir, Emtricitabine And Tenofovir Alafenamide
- **Active ingredients:** BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
- **Dosage form:** TABLET
- **Route:** —
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** CIPLA LTD
- **First approval:** 2025-10-14
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218766)
---
*AI Analytics · CC0 1.0*